Mer­ck touts pos­i­tive PhI­II re­sults for 21-va­lent pneu­mo­coc­cal vac­cine can­di­date

Mer­ck tout­ed pos­i­tive topline re­sults on Thurs­day sug­gest­ing its ex­per­i­men­tal 21-va­lent pneu­mo­coc­cal con­ju­gate vac­cine can­di­date best­ed Pfiz­er’s 20-va­lent shot in a Phase III tri­al.

The New Jer­sey phar­ma gi­ant’s V116 showed “sta­tis­ti­cal­ly sig­nif­i­cant im­mune re­spons­es com­pared to PCV20” in serotypes com­mon to both shots in a Phase III tri­al dubbed STRIDE-3 that en­rolled 2,600 vac­cine-naïve adults, Mer­ck an­nounced. Par­tic­i­pants were as­sessed 30 days af­ter be­ing vac­ci­nat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER